First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. - Wikidata - wikimedia - TriplyDB

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q37050472

about

Molecular Targeted Intervention for Pancreatic Cancer Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Recent treatment advances and novel therapies in pancreas cancer: a review.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells?Targeting the epidermal growth factor receptor in solid tumors: focus on safety.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis

P2860

Q26798453-255D0895-6FD5-47B0-AD17-148BE682FFA2 Q28082919-D0D49B55-B0FD-4A8C-AA9F-EA064A37A2F7 Q33625168-CA23B7D8-8C28-4300-B1E4-AB7F27AE015C Q36234132-41B1690A-63CE-4520-A637-8EA83A8F8CF6 Q37603012-C46E2C59-AA31-423A-9623-8654A55C8AD2 Q38200654-F9AF2C48-7B93-4533-AE85-FD07FC0FE076 Q38891976-DA96A396-9FFE-4F5F-917B-A3414062EEF7 Q57817700-89016627-6144-4B6B-8BF1-033F224D58D8

P2860

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

http://www.wikidata.org/entity/Q37050472

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@en

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@nl

type

label

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@en

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@nl

prefLabel

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@en

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@nl

P1433

Q37050472-4CB037D2-E900-4EE4-9588-BAB159A0C1D2

P1476

Q37050472-1627C0A4-2057-4FA9-BEEC-1DE59B457702

P2093

Q37050472-4776CB0F-2602-4B0E-A879-218881B0D816

Q37050472-5730324E-C293-4E80-89A8-9520F11267A7

Q37050472-5EE65F40-F384-4780-B22C-2AB08113DB14

Q37050472-BC5D71EF-2B95-4415-843C-973326033255

Q37050472-BD65BF6C-3742-4853-A3F9-446A1E20C572

Q37050472-FC68B585-66AE-4BDB-A3AC-521769418FA1

Q37050472-FC7847A6-C179-453F-BFC1-52A499CC094E

P2860

Q37050472-033E5CB5-6331-49C8-97CE-A75DB7E7B7A9

Q37050472-0BAAC673-51A5-45BB-B5C5-0CA8C48460B0

Q37050472-1A665AB9-EAC8-4B98-8EFC-1AF7553FDF55

Q37050472-400E994C-1DE3-451B-870A-5B26F602B773

Q37050472-547F8A9E-5545-4EE8-B4D7-52311697832F

Q37050472-6054F774-E8D2-4ECE-9868-EA244FE395AB

Q37050472-61FDA931-24F1-4F6E-A609-441184616FEA

Q37050472-652C71EA-7EF2-4829-A339-DC06D70B36A5

Q37050472-6FB63255-FFEE-489F-AE9C-C2CA7C26A015

Q37050472-8E2A8C71-2B32-44AC-B2B6-D12B9854AA73

P304

Q37050472-C02CFED6-6C6B-4B2D-87B8-4F1E8F7187AC

P31

Q37050472-6817382A-131D-4874-89ED-47A053B9D35C

P356

Q37050472-A370283D-BE61-4564-B1A1-7361D3FC0D13

P407

Q37050472-B620D1FF-C889-41CE-B416-E6DC768B5E56

P433

Q37050472-17286D01-2336-437F-A67D-9B0243A1A1A8

P478

Q37050472-7526D9AF-C6D0-4EF1-9B5A-206565BDE534

P50

Q37050472-4D053005-BF90-41C7-81F9-2B685D6DF39C

Q37050472-6B142E42-5824-410F-84CB-CA4F23469A75

Q37050472-B03A066A-68FB-4951-86F5-5BB8801CE7D0

P577

Q37050472-54F23AB6-8489-4DAE-877F-8155F2E5BB9B

P698

Q37050472-E1621C3C-F06E-427F-A699-CD783C13E65B

P932

Q37050472-6B9E06F9-C3E9-4241-B165-0E1289F8D54A

P356

WJG.V19.I28.4511

P1433

World Journal of Gastroenterology

P1476

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

@en

P2093

Alain Gelibter

http://www.w3.org/2001/XMLSchema#string

Enzo Maria Ruggeri

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Giovanni Mansueto

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Teresa Gamucci

http://www.w3.org/2001/XMLSchema#string

Vanja Vaccaro

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Erlotinib in previously treated non-small-cell lung cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer

P304

4511-4519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V19.I28.4511

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Isabella Sperduti

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23901226

http://www.w3.org/2001/XMLSchema#string

P932

3725375

http://www.w3.org/2001/XMLSchema#string